Avenue Therapeutics ATXI
OTC ATXI
$0.38 -0.03 (-8.33%)
As of: Oct 23, 2026 · 9:30 AM EDT

Avenue Therapeutics (ATXI) Return on Sales [ROS] (2025 - 2026)

Updated

Avenue Therapeutics' Return on Sales [ROS] was -206.34% in Q2 2026, down 227.49 percentage points from 21.15% a year earlier.

Analysis

Avenue Therapeutics (ATXI) Return on Sales [ROS] (2025 - 2026) Analysis & Trends

For FY2025, Return on Sales [ROS] at Avenue Therapeutics came in at -219.59%.

  • Quarterly Return on Sales [ROS] has moved between -279.77% (Q3 2025) and 21.15% (Q2 2025) over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 24.35%
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 37.86%
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn -3.52%
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 32.97%
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 20.57%
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 34.95%
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn -133.21%
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 28.37%
10 Avenue Therapeutics 1.32 Mn -9.61 Mn - -206.34%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -206.34%
Dec 31, 2025 -219.66%
Sep 30, 2025 -279.77%
Jun 30, 2025 21.15%
API Access

Avenue Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=ATXI&period=max&api_key=YOUR_API_KEY